Stephen J Greene Selected Research

Torsemide (Demadex)

10/2022	Ascertaining Death Events in a Pragmatic Clinical Trial: Insights From the TRANSFORM-HF Trial.
1/2022	An evaluation of torsemide in patients with heart failure and renal disease.
11/2021	Diuretic Changes, Health Care Resource Utilization, and Clinical Outcomes for Heart Failure With Reduced Ejection Fraction: From the Change the Management of Patients With Heart Failure Registry.
1/2021	Pragmatic Design of Randomized Clinical Trials for Heart Failure: Rationale and Design of the TRANSFORM-HF Trial.
1/2019	Death: The Simple Clinical Trial Endpoint.
1/2018	Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'?

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stephen J Greene Research Topics

Disease

131	Heart Failure 10/2022 - 09/2012
7	Hypotension (Low Blood Pressure) 01/2022 - 09/2012
6	Myocardial Infarction 12/2020 - 11/2013
6	Diabetes Mellitus 01/2019 - 12/2012
5	Atrial Fibrillation 01/2021 - 12/2013
4	Stroke (Strokes) 01/2022 - 11/2013
4	Type 2 Diabetes Mellitus (MODY) 01/2022 - 12/2019
4	Coronary Artery Disease (Coronary Atherosclerosis) 01/2022 - 07/2014
3	Hyperkalemia 01/2022 - 03/2013
3	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2017
3	Dyspnea (Shortness of Breath) 11/2021 - 01/2016
3	Chronic Renal Insufficiency 01/2021 - 06/2014
3	Acute Coronary Syndrome 11/2020 - 11/2013
3	Cardiovascular Diseases (Cardiovascular Disease) 06/2019 - 07/2016
3	Renal Insufficiency (Renal Failure) 01/2019 - 02/2013
2	COVID-19 01/2022 - 01/2022
2	Fibrosis (Cirrhosis) 01/2022 - 05/2020
2	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2022
2	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 01/2021
2	Hypertension (High Blood Pressure) 01/2018 - 04/2016
2	Systolic Heart Failure 10/2016 - 09/2014
2	Body Weight (Weight, Body) 12/2014 - 12/2013
1	Myocardial Ischemia (Ischemic Heart Diseases) 10/2022
1	Frailty 01/2022
1	Weight Gain 11/2021
1	Edema (Dropsy) 11/2021
1	Kidney Diseases (Kidney Disease) 01/2021
1	Weight Loss (Weight Reduction) 01/2021
1	Substance-Related Disorders (Drug Abuse) 01/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 11/2020
1	Iron Deficiencies 04/2019
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2018
1	Disease Progression 01/2018
1	Cicatrix (Scar) 04/2017
1	Ischemia 04/2017

Drug/Important Bio-Agent (IBA)

16	Tolvaptan FDA Link 01/2018 - 11/2012
15	Vasopressins (Vasopressin)IBA 01/2018 - 11/2012
12	Brain Natriuretic Peptide (Natrecor)FDA Link 06/2022 - 01/2015
12	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2022 - 12/2012
12	DiureticsIBA 01/2022 - 12/2012
11	SodiumIBA 01/2022 - 02/2013
11	Angiotensin Receptor AntagonistsIBA 01/2022 - 12/2012
8	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2018
8	Natriuretic PeptidesIBA 01/2017 - 02/2013
7	sacubitril and valsartan sodium hydrate drug combinationIBA 12/2021 - 01/2018
7	Pharmaceutical PreparationsIBA 01/2019 - 04/2014
6	Torsemide (Demadex)FDA LinkGeneric 10/2022 - 01/2018
6	Biomarkers (Surrogate Marker)IBA 01/2022 - 10/2013
6	Mineralocorticoid Receptor AntagonistsIBA 01/2022 - 09/2014
6	Neprilysin (Neutral Endopeptidase)IBA 01/2022 - 01/2018
6	Angiotensin Receptors (Angiotensin II Receptor)IBA 01/2022 - 01/2018
5	Furosemide (Lasix)FDA LinkGeneric 10/2022 - 01/2019
5	SymportersIBA 01/2022 - 12/2020
5	aliskiren FDA Link 01/2018 - 03/2013
4	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 12/2020
3	vericiguatIBA 01/2022 - 12/2015
3	CreatinineIBA 01/2022 - 05/2014
3	Sodium-Glucose Transport ProteinsIBA 01/2022 - 12/2019
3	pro-brain natriuretic peptide (1-76)IBA 01/2020 - 01/2015
3	TroponinIBA 12/2018 - 01/2018
3	Digoxin (Digitek)FDA LinkGeneric 01/2018 - 12/2012
3	Soluble Guanylyl CyclaseIBA 12/2015 - 09/2012
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 10/2022 - 11/2014
2	Metformin (Glucophage)FDA LinkGeneric 01/2022 - 01/2022
2	dapagliflozinIBA 01/2022 - 11/2020
2	Sodium Potassium Chloride Symporter Inhibitors (Loop Diuretics)IBA 01/2019 - 01/2015
2	Renin InhibitorsIBA 01/2018 - 10/2013
2	ReninIBA 01/2018 - 11/2017
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 07/2016 - 02/2016
2	Antidiuretic Hormone Receptor AntagonistsIBA 01/2015 - 05/2014
2	Hemoglobins (Hemoglobin)IBA 12/2014 - 05/2014
2	Warfarin (Coumadin)FDA LinkGeneric 06/2014 - 11/2013
1	Metolazone (Diulo)FDA LinkGeneric 11/2021
1	Bumetanide (Bumex)FDA LinkGeneric 11/2021
1	Biological ProductsIBA 01/2021
1	NitratesIBA 01/2021
1	Sodium-Glucose Transporter 1IBA 01/2021
1	omega-Chloroacetophenone (Mace)IBA 12/2020
1	N- benzhydryl- 5- (2- (methylamino)propanamido)- 3- (3- methylbutanoyl)- 6- oxodecahydropyrrolo(1,2- a)(1,5)diazocine- 8- carboxamideIBA 11/2020
1	Liraglutide FDA Link 01/2020
1	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2020
1	Cystatin CIBA 01/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 12/2019
1	IronIBA 04/2019
1	Polysaccharides (Glycans)IBA 04/2019
1	Spironolactone (Aldactone)FDA LinkGeneric 01/2019
1	AldosteroneIBA 01/2019
1	Troponin IIBA 12/2018
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 12/2018
1	AngiotensinsIBA 11/2017

Therapy/Procedure

63	Therapeutics 10/2022 - 12/2012
7	Patient Readmission 01/2022 - 03/2013
3	Secondary Prevention 10/2022 - 07/2016
3	Length of Stay 01/2022 - 10/2015
2	Contraindications 01/2022 - 01/2019
1	Surgical Amputation (Amputations) 01/2021
1	Heart-Assist Devices 01/2021
1	Transitional Care 01/2021
1	Bariatric Surgery 12/2020
1	Intravenous Administration 01/2017